NNNN

Anbio Biotechnology

Sep 22 • 03:59PM ET

37.78

-4.81 -11.29 %

Healthcare • Medical Instruments & Supplies • Germany • NASD

Index	-	P/E	623.43	EPS (ttm)	0.06	Insider Own	9.57%	Shs Outstand	42.29M	Perf Week	-11.21%
Market Cap	5.44B	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	39.69M	Perf Month	-23.51%
Enterprise Value	5.42B	PEG	-	EPS next Q	-	Inst Own	0.07%	Short Float	0.41%	Perf Quarter	100.42%
Income	2.56M	P/S	614.26	EPS this Y	-	Inst Trans	-45.61%	Short Ratio	1.22	Perf Half Y	399.74%
Sales	8.85M	P/B	89.75	EPS next Y	-	ROA	13.83%	Short Interest	0.16M	Perf YTD	554.77%
Book/sh	0.42	P/C	446.32	EPS next 5Y	-	ROE	15.00%	52W High	55.65 -32.11%	Perf Year	-
Cash/sh	0.08	P/FCF	2416.09	EPS past 3/5Y	-50.61% -	ROIC	14.40%	52W Low	5.18 629.34%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	2522.81	Sales past 3/5Y	-40.18% -	Gross Margin	71.91%	Volatility	5.68% 6.90%	Perf 5Y	-
Dividend TTM	-	EV/Sales	612.89	EPS Y/Y TTM	5.21%	Oper. Margin	24.34%	ATR (14)	3.30	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.71	Sales Y/Y TTM	21.97%	Profit Margin	28.95%	RSI (14)	32.64	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	10.71	EPS Q/Q	-267.38%	SMA20	-15.74%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.00	Sales Q/Q	-36.00%	SMA50	-18.54%	Rel Volume	0.65	Prev Close	42.59
Employees	27	LT Debt/Eq	0.00	Earnings	-	SMA200	63.11%	Avg Volume	133.44K	Price	37.78
IPO	Feb 19, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	86,511	Change	-11.29%

Aug-08-25 09:05PM	Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System (GlobeNewswire) +10.88% -7.89%
Jul-09-25 10:31AM	Here Is What You Need To Know Before Investing In Anbio Biotechnology (NNNN) (Insider Monkey) +14.50%
Jul-04-25 06:00AM	The IPO market in 2025 is being driven by a clear theme bigger is better (Yahoo Finance)
May-15-25 01:05AM	Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions (GlobeNewswire) +6.12%
Feb-20-25 09:50AM	Anbio Biotechnology Announces Closing of Initial Public Offering (GlobeNewswire)
06:10PM	Loading…
Feb-18-25 06:10PM	Anbio Biotechnology Announces Pricing of Initial Public Offering (GlobeNewswire)

Anbio Biotechnology is a medical device company. It is focused on developing and manufacturing a range of in-vitro diagnostic (IVD) products. The company was founded on July 27, 2021 and is headquartered in Frankfurt, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NNNN

Anbio Biotechnology

Upgrade your FINVIZ experience